Can a pill stop you catching COVID after someone at home gets sick?
Yes. In this large trial, a 5-day course of the pill ensitrelvir cut the chance of getting sick with COVID-19 by 67 percent when people started it within three days of a household member’s symptoms.
When someone in your home tests positive for COVID-19, the rest of the household often waits and worries. Until now, there was no proven pill you could take to stop the virus from spreading to you. This study tested whether ensitrelvir, an oral antiviral, could change that. The idea is simple: take the drug soon after you have been exposed, before the virus has a chance to take hold.
What the data show
The results were clear and strong. Researchers ran a Phase 3 trial called SCORPIO-PEP that included 2,387 household contacts of people with PCR-confirmed COVID-19. Each contact was randomly assigned to take either ensitrelvir or a placebo, a dummy pill with no active drug, for five days. Treatment started within 72 hours of the sick household member first showing symptoms.
By the end, only 2.9 percent of people in the ensitrelvir group developed symptomatic, lab-confirmed COVID-19. In the placebo group, 9.0 percent got sick. That works out to a 67 percent drop in risk, with a risk ratio of 0.33 and a strong statistical result (P<0.001). In plain terms, the pill prevented about two out of every three infections that would otherwise have happened.
Dr. Kumar’s Take
What I find exciting here is that this is the first oral antiviral shown to actually prevent COVID-19 after exposure, not just treat it after you are already sick. For years we have had pills for people who test positive, but nothing simple to offer the worried spouse or parent in the same house. A two-thirds reduction in infections is a meaningful number, and the fact that it came from a large, well-designed, placebo-controlled trial gives me real confidence in it. I am also reassured by the safety picture, which I will get to below. My honest caveat is that prevention drugs work best when started fast, so timing and access will matter a lot in the real world.
How the study was done
This was a global, double-blind, placebo-controlled trial, which is the gold standard for testing a drug. Double-blind means neither the participants nor the researchers knew who got the real pill and who got the placebo until the study ended. That design helps rule out wishful thinking and bias. Because everyone was a household contact of a confirmed case, these were people with a genuine, recent exposure rather than a vague risk. The 72-hour window also reflects how the drug would likely be used in practice, since households usually learn about a positive case quickly.
Safety and side effects
A prevention drug is only useful if healthy people can take it without trouble, and this is where ensitrelvir looked strong. Side effects were almost identical between the two groups. About 15.1 percent of people taking ensitrelvir reported an adverse event, compared with 15.5 percent of those taking the placebo. When a real drug causes about the same rate of side effects as a sugar pill, that tells me the drug itself is well tolerated. For a medicine meant to be handed out to people who are not even sick yet, that kind of clean safety profile is important.
Practical Takeaways
- If a household member tests positive for COVID-19, speed matters: the trial started ensitrelvir within 72 hours of the sick person’s first symptoms, so ask your doctor quickly about your options.
- Remember that ensitrelvir is a preventive pill taken after exposure, not a substitute for vaccination, good ventilation, or other basic precautions.
- Availability and approval for this specific use vary by country, so check with your physician or pharmacist about whether the drug is an option where you live.
- Do not assume side effects are a barrier, since in this trial the pill caused about the same rate of adverse events as a placebo.
Related Studies and Research
- single-dose psilocybin vs placebo: first double-blind depression trial
- sleep duration and dementia risk: 7 hours protects your brain long-term
- mindfulness meditation for chronic insomnia: randomized controlled trial results
- saffron extract improves sleep quality: randomized double-blind trial
FAQs
How is ensitrelvir different from existing COVID pills like Paxlovid?
The biggest difference shown in this trial is the goal. Earlier antivirals were tested mainly to treat people who already tested positive and reduce how sick they get. This study tested ensitrelvir for prevention, meaning it was given to exposed but still-healthy household contacts to stop infection before it started. That makes it the first oral antiviral proven to work for postexposure prevention. It is also taken as a once-daily course over five days, which can be simpler than some other regimens.
How fast do you have to take it for it to work?
Timing appears to be central to the benefit. In this trial, people began the five-day course within 72 hours of the index case, the first sick person in the home, showing symptoms. Antivirals generally work best early, before the virus has multiplied widely in the body. Waiting too long likely reduces the benefit, which is why fast testing and a quick call to your doctor matter. The study did not show results for people who started much later than three days.
Does this mean I no longer need a COVID vaccine?
No, and that is an important point. This trial only measured whether the pill prevented infection after a known household exposure over a short window. It did not compare the drug to vaccination or test it as a long-term shield against every future exposure. Vaccines and antivirals do different jobs, and the smartest approach uses the right tool at the right time. Think of ensitrelvir as a possible emergency option after exposure, not a replacement for staying up to date on shots.
Bottom Line
This trial marks a genuine first: an oral antiviral that prevents COVID-19 after you have been exposed at home. By cutting symptomatic infections from 9.0 percent down to 2.9 percent, ensitrelvir reduced the risk by two-thirds, and it did so with a side-effect rate no different from placebo. If approved for this use, a simple five-day pill started soon after a household member gets sick could give families a powerful new way to protect each other.
